Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.03.16	Regeneron: Sarilumab Shows Stronger Efficacy Than Adalimumab In Phase 3 Study (RTTNews)
28.02.16	Eylea, Avastin Or Lucentis - Which Is More Efficacious In Treating DME? (RTTNews)
09.02.16	EARNINGS SUMMARY: Details of Regeneron Pharmaceuticals Q4 Earnings Report (RTTNews)
08.01.16	Regeneron, Sanofi: FDA Accepts Sarilumab BLA For Review - Quick Facts (RTTNews)
01.01.16	Looking For Novel New Drug Approvals Of 2015? Here's The List... (RTTNews)
11.12.15	Regeneron, Sanofi: UnitedHealth Selects Praluent Injection For Preferred Access (RTTNews)
24.11.15	Regeneron, Sanofi Fully Enroll ODYSSEY OUTCOMES Trial Of Praluent Injection (RTTNews)
08.11.15	Sanofi, Regeneron Announce Sarilumab Phase 3 Study Meets Co-primary End Point (RTTNews)
04.11.15	Regeneron Pharma Lifts FY15 Sales Growth Outlook For Eylea U.S. (RTTNews)
04.11.15	Regeneron Pharmaceuticals Bottom Line Rises 37% In Q3 (RTTNews)
02.11.15	ALXA Gets It Back, REGN's Eylea Keeps Adding New Indications, Smooth Flows PTLA (RTTNews)
30.10.15	Regeneron Announces EU Approval Of EYLEA - Quick Facts (RTTNews)
28.09.15	Regeneron And Sanofi Say EU Approves Praluent To Treat Hypercholesterolemia (RTTNews)
01.09.15	Regeneron And Sanofi Announce New Positive Praluent Phase 3 Data Presented (RTTNews)
04.08.15	Regeneron Pharma Q2 Profit Rises; Lifts 2015 EYLEA U.S. Net Sales Growth View (RTTNews)
04.08.15	EARNINGS SUMMARY: Details of Regeneron Pharmaceuticals Q2 Earnings Report (RTTNews)
28.07.15	Regeneron, Sanofi To Jointly Advance PD-1, Other New Immuno-oncology Antibodies (RTTNews)
24.07.15	Sanofi: FDA Okays Praluent To Treat Certain Patients With High Cholesterol (RTTNews)
24.07.15	Regeneron:CHMP Recommends EU Approval Of Praluent To Treat Hypercholesterolemia (RTTNews)
09.07.15	Aethlon To Be Uplisted To NASDAQ, CLLS Hits Milestone, LXK Gets FDA Nod (RTTNews)
09.07.15	Regeneron:Phase3 Odyssey Japan Trial Of Praluent Injection Met Primary Endpoint (RTTNews)
26.06.15	Regeneron: Bayer Gets Approval For EYLEA Injection In Japan To Treat RVO (RTTNews)
10.06.15	FDA Panel Backs REGN's Cholesterol Drug, SAGE Cheered Up, Keep Watch Over TXMD (RTTNews)
10.06.15	FDA Panel Okays Praluent Injection To Treat Hypercholesterolemia (RTTNews)
21.05.15	Regeneron, Sanofi Report Positive Phase 3 Study Results Of Sarilumab In RA (RTTNews)
26.03.15	EBS, REGN Get FDA Nod, OVAS To Deliver, Recro Recuperates, Watch Out For ZSAN (RTTNews)
25.03.15	Regeneron : FDA Oks New Treatment For Diabetic Retinopathy In Patients With DMS (RTTNews)
15.03.15	Sanofi Announces 18-Month Results Of ODYSSEY LONG TERM Trial With Praluent (RTTNews)
10.02.15	Regeneron Pharma Q4 Profit Climbs - Quick Facts (RTTNews)
26.01.15	Regeneron Pharma, Sanofi Say FDA Accepted For Priority Review BLA For Praluent (RTTNews)
23.01.15	Regeneron Pharma: EYLEA Injection Recommended For Approval By CHMP (RTTNews)
12.01.15	Regeneron, Sanofi Say Praluent MAA Accepted For Review By EMA (RTTNews)
12.01.15	SCYX Rises, ARGS Crashes, AMRI Opens Wallet, NPSP Snapped Up, TNXP On Watch (RTTNews)
09.01.15	Regeneron Pharma Says Two ODYSSEY Trials Met Primary Efficacy Endpoints (RTTNews)
02.12.14	FDA Lifts Hold On FLXN Study, All's Well With CPXX Trial, COMET Woes For EXEL (RTTNews)
01.12.14	Regeneron Says FDA Accepts Eylea Application For Priority Review (RTTNews)
20.11.14	Regeneron, Sanofi's Dupilumab Gets Breakthrough Therapy Designation From FDA (RTTNews)
19.11.14	Regeneron, Sanofi Announce New Positive Results From Six Phase 3 ODYSSEY Trials (RTTNews)
18.11.14	Regeneron & Bayer HealthCare's Eylea Gets Japanese Nod For Macular Edema (RTTNews)
11.11.14	Regeneron, Sanofi Say Phase 2b Trial Of Dupilumab Meets Primary Endpoint (RTTNews)
04.11.14	Regeneron Pharmaceuticals Q3 Profit Falls - Quick Facts (RTTNews)
20.10.14	Regeneron, Sanofi Begins Phase 3 Trial Of Dupilumab - Quick Facts (RTTNews)
20.10.14	Sanofi, Regeneron Begin Phase 3 Study For Eczema Drug Dupilumab (RTTNews)
17.10.14	Amgen Files Patent Infringement Lawsuit Against Sanofi And Regeneron (RTTNews)
17.10.14	Regeneron Pharma's EYLEA Injection Shows Greater Gains In Visual Acuity (RTTNews)
07.10.14	ACT Opens Wallet, ADHD Craters, CMRX Focuses On Ebola, REGN Gets FDA Nod (RTTNews)
07.10.14	Regeneron Pharma Says FDA Approves Expanded Use Of Eylea (RTTNews)
30.09.14	Regeneron, Sanofi Report Positive Phase 2 Dupilumab Results In CSwNP (RTTNews)
30.09.14	Regeneron, Sanofi Report Positive Phase 2 Top-line Dupilumab Results For CSwNP (RTTNews)
22.09.14	Bayer' EYLEA Gets Approval In Japan To Treat Myopic Choroidal Neovascularization (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

19.11.24		Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen
31.10.24		NASDAQ-Handel NASDAQ 100 schlussendlich in Rot
31.10.24		NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone
31.10.24		NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell
31.10.24		Zurückhaltung in New York: So performt der NASDAQ 100 aktuell
31.10.24		Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus
31.10.24		Zurückhaltung in New York: NASDAQ 100 zum Handelsstart im Minus
31.10.24		Donnerstagshandel in New York: NASDAQ Composite verliert zum Handelsstart

19.11.24

Zuversicht in New York: NASDAQ 100 mit positivem Vorzeichen

31.10.24

NASDAQ-Handel NASDAQ 100 schlussendlich in Rot

31.10.24

NASDAQ Composite-Handel aktuell: NASDAQ Composite am Donnerstagnachmittag in der Verlustzone

31.10.24

NASDAQ 100-Handel aktuell: Das macht der NASDAQ 100 aktuell

31.10.24

Zurückhaltung in New York: So performt der NASDAQ 100 aktuell

31.10.24

Angespannte Stimmung in New York: NASDAQ Composite liegt mittags im Minus